Fund moves
10.0%Stake · was 10.0%
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
PPBT · NASDAQ · Pharmaceutical Preparations · Foreign private issuer
Purple Biotech (PPBT) · oqro.io/stocks/PPBT · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$1.53−0.005 (−0.33%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Purple Biotech is on record in SEC filings since 2006.
No open-market sale by an insider of Purple Biotech (PPBT) was filed with the SEC in the last 90 days.
No trade in Purple Biotech (PPBT) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−80.0% (−$6.10) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $7.62 on Nov 20, 2025 to $1.53 on Nov 20, 2026 (−80.0%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Rehovot, Israel. Foreign private issuer: reports on Form 20-F or 40-F. Its directors and officers file insider-trading forms (Form 4) only since 18 March 2026.
Last 12 months
−80.0%
Market value
–
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 16K shares sold short, −3.8% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Ayrton Capital LLC
13G · passive · Crossed 5% · 103K shares · filed Nov 12, 2026
Mitchell P. Kopin
13G · passive · Amended · 207M shares · filed Nov 10, 2026
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Off-exchange trading: 48.1% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (2.7% on ATS, 45.4% with other brokers), below its 26-week average of 54.1%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: IBKR ATS (41.8%), UBS ATS (16.8%), LEVEL ATS (8.7%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Every annual report has a section where the company's managers explain the year's results (Item 5, Operating and financial review). In this report it runs to about 4,000 words.
We are a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity. We are focused on advancing our lead program, CAPTN-3 - a platform of masked tri-specific antibodies that simultaneously target tumors while engaging both T cells and NK cells. Our masking technology confines immune activation to the tumor microenvironment, significantly expanding the therapeutic window versus unmasked T-cell engagers. The platform’s lead candidate, IM1240 is advancing toward the clinic and IM1305 is in preclinical development.
And 7 more headings in the filing.
Source: SEC EDGAR, Form 20-F filed Mar 19, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind